

Prof. Dr. Gold, Ralf

* September 12, 1960
Ruhr-University Bochum
Faculty of Medicine
Chair of Neurology
St. Josef-Hospital
Gudrunstr. 56, 44791 Bochum, Germany
ralf.gold@rub.de
<http://neurologie.klinikum-bochum.de/>



Education:

1980-1986 Study of Medicine, University Würzburg, **1986** Dr. med. (magna cum laude), Faculty of Medicine, University Würzburg, **1989-1992** DFG postdoctoral fellowship, Max-Planck Institute, Neuroimmunology, Würzburg and München (director H. Wekerle), **1996** Habilitation, venia legendi for Neurology, Faculty of Medicine, University Würzburg

Positions:

1995 Consultant in Neurology, **1997-2002** Head, clinical research group for MS and Neuroimmunology, Neurology, University Würzburg with full professorship **since 2001**. **2003** Chair, Institute for Experimental and Clinical Neuroimmunology, University Göttingen, **since 2006** Chair of Neurology, Ruhr-University Bochum

Scientific Honours / Awards:

1980-1986 Scholarship, national scholarship foundation, **1996** Heinrich-Pette-Award of the German Neurological Society, **1997** Langheinrich-Award of the Berlin Society for Psychiatry und Neurology, **2000** Ernst Klüh-Award of the German Hospital Society, **2008** Hans-Georg Mertens-Award of the German Neurological Society, **2011** Sobek Preis

Further activities (selection):

1999-2003 Founding member, secretary of the SFB 581 „Molecular Models for Diseases of the Nervous System“, **since 1997** Board member of the scientific advisory committee of the German MS Society, **since 2007** Member of the ECTRIMS councils, ISNI Advisory Board, **since 2008** Member of the DFG advisory board of neurosciences, **since 2009** Founding member, board of the BMBF (Federal Ministry of Education and Research)-network multiple sclerosis, Executive board ECTRIMS, panel leader EFNS Demyelinating Diseases

Research areas:

Molecular mechanisms of neuroprotection in MS, translational MS medicine, T cell directed therapies in neuroimmunology, surrogate markers for individualized medicine

10 Publications:

- Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, **Gold R** (2009) Treatment of PML associated with natalizumab monotherapy. *New England J Med* 361:1075-1080
- Stegbauer J, Lee DH, Seubert S, Ellrichmann G, Manzel A, Kvakhan H, Muller DN, Gaupp S, Rump LC, **Gold R**, Linker RA. (2009) Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. *Proc Natl Acad Sci USA* 106:14942-14947
- Kappos L, **Gold R**, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN (2008) BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. *Lancet* 372:1463-1472
- Linker RA, Kruse N, Israel S, Wei T, Seubert S, Hombach A, Holtmann B, Luhder F, Ransohoff RM, Sendtner M, **Gold R** (2008) Leukemia inhibitory factor deficiency modulates the immune response and limits autoimmune demyelination: a new role for neurotrophic cytokines in neuroinflammation. *J Immunol* 180:2204-2213
- Stasziolek M, Bayas A, Kruse N, Wiczarkowicz A, Toyka KV, **Gold R**, Selmaj K (2006) Impaired maturation and function of plasmacytoid dendritic cells in multiple sclerosis. *Brain* 129:1293-1305
- Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Hanke T, Hünig T, Kerkau T, **Gold R** (2005) Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. *J Exp Med* 202, 445-455
- Sommer C, Weishaupt A, Brinkhoff J, Biko L, Wessig C, **Gold R**, Toyka KV (2005) Paraneoplastic stiff-person syndrome: Passive transfer to the rat with IgG antibodies to amphiphysin. *Lancet* 365:1406-1411
- Visan IA, Weishaupt A, Hofstetter HH, Toyka KV, Hünig T, **Gold R** (2004) Tolerance induction by intrathymic expression of myelin P0 protein. *J Immunol* 172, 1364-1370
- Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, **Gold R** (2003) Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. *Brain* 126:1895-1904
- Linker RA, Gaupp S, Mäurer M, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, **Gold R** (2002) CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. *Nature Med* 8:620-624